https://www.urotoday.com/journal/everyday-urology-oncology-insights/articles/113270-optimizing-turbt-and-optical-diagnostics-in-bladder-cancer-2.html

Ny klinikk med BLC, Reston Hospital Center. Ikke oppført på Cysview.

https://www.biospace.com/article/reston-hospital-first-in-northern-virginia-to-offer-innovative-procedure-to-improve-detection-of-certain-bladder-cancers/?fbclid=IwAR12vwFBwOSOYQx2kZYm9zy_0K4lryK8R_lYxn39alR0LPZ6K6TJB0j6QFE

https://www.kusi.com/new-technology-improves-diagnosis-of-bladder-cancer/

Denne er også ny og kan faktisk ikke se at denne heller er oppført på Cysview.
Her snakker vi såvidt jeg kan se også flexiskop.
"“At University Urology, patients with known or suspected bladder cancer can now undergo diagnostic procedures performed by physicians who have been specially trained in the use of this innovative technology,” Terry said. “We are also able to perform BLC and bladder biopsies in the office setting, if needed.”

https://www.usahealthsystem.com/news/university-urology-blue-light

Klinikk nummer 131 oppført på Cysview.com nå.

Lahey Hospital and Medical Center

Klinikk nummer 132 oppført på Cysview.com nå.

Montrose Memorial Hospital

Klinikk nummer 133 oppført på Cysview.

St. Mary’s Medical Center

https://www.cysview.com/about/where-its-available/?locate=

Oppdatert Topp 20 som øker litt gjennom forrige uke.

Nordnet Liv + ca. 25k

Fondsfinans Global Helse + ca. 10k

https://photocure.com/investor/largest-shareholders/

Klinikk nummer 134 oppført på Cysview.

Prestige Medical Group 720 N. Tustin Ave, Suite 104 Santa Ana, CA 92705

https://photocure.com/news/photocure-to-present-at-norne-securities-vekst--verdi-aksjeseminar-in-vilnius/

https://photocure.com/globalassets/investor-relations/presentations/2019-pres/pho-comp-pres-2019.09.20-norne-vilnius.pdf

Klinikk nummer 135 oppført på Cysview.

Reston Hospital Center, 1850 Town Center Pkwy, Reston, VA 20190

Kan være den samme som denne, har ikke fått sjekket grundig nok enda:

AndyHagen
12.09.2019 kl 21:04
1377
Ny klinikk med BLC, Reston Hospital Center. Ikke oppført på Cysview.

https://www.biospace.com/article/reston-hospital-first-in-northern-virginia-to-offer-innovative-procedure-to-improve-detection-of-certain-bladder-cancers/?fbclid=IwAR12vwFBwOSOYQx2kZYm9zy_0K4lryK8R_lYxn39alR0LPZ6K6TJB0j6QFE

https://www.thieme-connect.com/products/ejournals/abstract/10.1055/a-1007-8497

Abstract

Background Photodynamic Diagnosis (PDD) is widely used today for the diagnosis and treatment of superficial bladder cancer. This study aimed to analyse the impact of using this technique on recurrence rate, residual tumour rate and progression-free survival.

Materials and methods We conducted this study retrospectively in our unit between 10/2014 and 02/2018. We divided our patients into 2 groups: white light group, 49 patients who underwent primary bladder tumour resection with white light transurethral resection of bladder tumour (WL-TURB), and blue light group, 49 patients treated with blue light transurethral resection of bladder tumour (BL-TURB) with PDD. Patients in both groups were followed up for one year. We collected data for tumour recurrence for the first year, 3-month and 1-year relapse-free survival and 1-year progression-free assessment pursuant to the EORTC risk classification by Sylvester 2006. Furthermore, the residual tumour rate was determined by re-TURB.

Results The following results were found independent of age, gender and histological findings: Residual tumour rate: blue light group 13.95 % vs. white light group 32.6 %, (p 0.02, OR 3.8, CI 95 % [1.17 – 12.85]).; 3-month relapse-free survival: blue light group 87.7 % vs. white light group 67.4 % (p 0.02, HR 3.18, CI 95 % [1.20 – 8.42]); 1-year relapse-free survival: blue light group 77.6 % vs. white light group 55.1 % (p 0.015, HR 2.56, CI 95 % [1.20 – 5.45]); 1-year progression-free survival: blue light group 95.9 % vs. white light group 79.6 %, p 0.03, HR 5.23, CI 95 % [1.11 – 24.53])

Conclusion The use of hexaminolevulinate significantly reduces the risk of residual tumours compared with conventional TURB. The PDD technique significantly improved 3- and 12-month recurrence-free survival, especially in low and medium-risk tumours, and 1-year progression-free survival, especially in high-risk tumours

https://twitter.com/EUplatinum/status/1177619670838513676?s=20

Klinikk nummer 136 oppført på Cysview.

VA Long Beach Healthcare System
5901 East 7th Street Long Beach, CA 90822

https://www.sciencedirect.com/science/article/abs/pii/S0302283819306748?dgcid=rss_sd_all

https://photocure.com/news/bladdr_hexvix_abstracts/

Sometimes when we write stories, we have no idea who is impacted; other times, we are able to bring about change that we had no way of foreseeing.

In August 2018, I wrote a feature on Alex Huang, his battle with bladder cancer and his subsequent role as an ambassador for the greater Hamilton area with Bladder Cancer Canada. He was trying to promote the local support group available to other bladder cancer patients. Not only did the article help bring in some new members, but through one of those new members, Alex learned about blue-light cystoscopy, a new technology that is showing huge promise around the world as a better way to detect, and ultimately treat, bladder cancer. Now, Alex is working to get area hospitals to commit to bringing the technology here — and once they do, he’s ready to start fundraising, and I’m ready to write the update.

https://www.sachem.ca/news-story/9632150-sachem-and-gazette-stories-that-moved-our-journalists/

https://twitter.com/docsLMG/status/1181260563638292491?s=20

https://twitter.com/docsLMG/status/1181260564582014976?s=20

https://twitter.com/docsLMG/status/1181260565416759299?s=20

https://twitter.com/urotoday/status/1181825375023849473?s=20

Oppdatert Topp 20.
De har totalt redusert med minus ca. 15k.
Endringer:
Frank Stave + 20k(Økt jevnt med ca 15-18k pr uke siste tre uker)
Fondsfinans - 15k
Nordnet Livsforsikring -20k
Danske Bank - 1k

https://photocure.com/investor/largest-shareholders/

Klinikk nummer 137 oppført på Cysview.

Brigham and Women's Faulkner Hospital
1153 Centre St, Boston, MA 02130

For our in-licensed photodynamic product, Cevira®, it is actually a second-generation product. The first-generation product entered Phase II trials but was discontinued because it was not efficacious enough. The second-generation product has made improvement in design to increase its absorption, which should theoretically increase the sensitivity of the drug to photo-activation. In addition, the phototherapy device has been miniaturized so it can be implanted on the cervix. Patients can leave the hospital and remove the device easily by themselves once the treatment is completed. Importantly, the product has shown positive Phase II results, which finally gave us the confidence to invest.

https://pharmaboardroom.com/interviews/kevin-pan-ceo-asieris-china/?fbclid=IwAR2-oIWM8sEpFZOWBgpzjLOosf72ECSX7-1eq7eHZ3rOyS0Myd74z-fkcQ0

And this is not unique to this study either. We have seen the same thing with the flexible blue light study that we did where we were looking at detection of CIS with flexible blue lights, cystoscopy in the office. And we found the same thing, that cytology was not sensitive in picking up the high-grade cancers in many, many of the cases. In fact, all the lesions that were seen with blue light alone had negative cytology. So again, this is consistent with those results.

https://www.urotoday.com/video-lectures/bladder-cancer/video/mediaitem/1540-players-brightcove-net2019-10-15-19-14-58.html

https://www.urotoday.com/recent-abstracts/urologic-oncology/bladder-cancer/115420-photodynamic-versus-white-light-guided-treatment-of-non-muscle-invasive-bladder-cancer-a-study-protocol-for-a-randomised-trial-of-clinical-and-cost-effectiveness

https://twitter.com/ColinLinke/status/1185197537206132736?s=20

https://www.urotoday.com/video-lectures/bladder-cancer/video/1523-players-brightcove-net2019-10-10-16-32-07.html

Kan det komme noe om BLC i Athen nå i ettermiddag?
Vanskelig å si, men lov å håpe.

1545-1715
📷
Instructional Course 09: Management of Non-Muscle Invasive Bladder Cancer (NMIBC) - Are We Doing the Right Thing?
Chair: Makarand Khochikar, India
At the conclusion of this activity, participants will be able to:
Have a clarity on current strategies in the treatment of NMIBC, the most common yet not appropriately addressed cancer in urologic oncology.
Makarand Khochikar, India1545-1550
Introduction
Makarand Khochikar, India1550-1605
Optimizing the First TURBT - Technique, Do's and Dont's
Mark Soloway, United States1605-1620
Are We Over Indulging in Restaging TURBT
Ashish M. Kamat, United States1620-1635
Changing Paradigm in Intravesical Therapy for NMIBC
Badrinath Konety, United States1635-1715
Challenging Cases

https://www.siu-urology.org/congress-2019/scientific-programme

"We are proud that Hexvix® / Cysview® is included in studies intending to enhance Bladder Cancer treatment for patients around the world, focusing both on reducing the patient burden and the health care resources and costs. At Photocure we strongly believe that the use of Hexvix / Cysview with flexible cystoscopes in the surveillance and treatment of patients in the outpatient/office setting will give a large number of patients access to better management of their disease", says Dan Schneider, President and CEO of Photocure.

https://photocure.com/news/siu2019_athens/

https://www.urotoday.com/recent-abstracts/urologic-oncology/bladder-cancer/115896-diagnostic-performance-of-image-technique-based-transurethral-resection-for-non-muscle-invasive-bladder-cancer-systematic-review-and-diagnostic-meta-analysis.html

For bladder cancer detection, the urologists are the first in central Connecticut to use a new blue light cystoscopy technology to illuminate tumors in the bladder and identify smaller cancers earlier than ever before.

Certain tumors are hard to detect using traditional white light cystoscopy, but turn pink under the enhanced imaging provided by the blue light.

“Recurrence rates for bladder cancers are somewhere in the 50–70% range. Using blue light cystoscopy, depending on the tumor type, can reduce the risk of recurrence by about 40%, which means fewer trips to the operating room,” says Dr. Benjamin Ristau, UConn Health’s surgical director of urologic oncology.

https://twitter.com/UConn/status/1186666022692098048?s=20

Klinikk nummer 138 lagt til på Cysview.
Ronald Reagan UCLA Medical Center

The Ronald Reagan UCLA Medical Center (also commonly referred to as UCLA Medical Center or "RRMC") is a hospital located on the campus of the University of California, Los Angeles, in Westwood, Los Angeles, California, United States. It is currently ranked the 6th best hospital in the United States by U.S. News & World Report, and 1st in the West Coast.[2]

https://www.urotoday.com/conference-highlights/siu-2019/siu-2019-bladder/115945-siu-2019-re-turbt-yes-no-or-maybe.html?fbclid=IwAR2TW-In-4UeK10NC_iUVfIFTrUq93f9__hOMxaemrOCnph1NAil0f0vrkU

https://twitter.com/SWReports/status/1187080225533890561?s=20

https://www.talkingurology.com.au/syg/turbt/

Nå går det jaggu unna i USA!

Klinikk nummer 139, 140 og 141 oppført på Cysview.

Capital Health Medical Center - Hopewell

1 Capital Way Pennington, NJ 08534

Capital Health – Urology Specialists

1050 Stony Hill Road Yardley, PA 19067

Capital Health – Urology Specialists

Two Capital Way, Suite 407 Pennington, NJ 08534

https://twitter.com/PhotocureASA/status/1187658537884884995?s=20

http://www.e-fjs.org/article.asp?issn=1682-606X%3Byear%3D2019%3Bvolume%3D52%3Bissue%3D5%3Bspage%3D155%3Bepage%3D160%3Baulast%3DZang%3Btype%3D3&fbclid=IwAR14i_A8bddEl1sYYTBETpmzTh5MhiHNopu4xE14lpw2wzAErJMqdC7Ws4U

https://photocure.com/news/photocure-new-data-from-hexvix-trials-presented-at-the-bladdr-2019-congress/

https://twitter.com/radforsk/status/1188723343538774016?s=20

Kom plutselig over denne store studien som skal avsluttes i 2020.
Har selv aldri sett dette før, kanskje flere enn undertegnede som gjerne vil se.

https://ichgcp.net/clinical-trials-registry/NCT02660645?fbclid=IwAR0iSkilDn45b63ryQvV6fj1D28oGIozd_R-pfVOG4Fs6xnFKo-bb9sdu6M

https://photocure.com/news/photocure-asa-invitation-to-third-quarter-2019-results-presentation-and-webcast/

Da er er den første av to konferanser denne helgen og neste uke igang.
Har ikke lest programmet, men antar at Pho deltar direkte eller indirekte siden selskapet er nevnt:

Thank you
2019 Exhibitors
Photocure
https://whova.com/web/wsaua_201911/#exhibitor

https://drive.google.com/file/d/1ssbvPOCb188MLGM4hVRNntB-hv9uqras/view
https://drive.google.com/file/d/1JdSuy693OtiorEsPOUcIh8dwHJOq2sof/view

https://monterey19.wsaua.org/

https://twitter.com/urotoday/status/1190942194712162305?s=20

https://www.urotoday.com/recent-abstracts/urologic-oncology/bladder-cancer/115737-suna-2019-utilizing-change-management-for-successful-implementation-of-blue-light-cystoscopy.html?pk_campaign=Roe_SocialSUNA19_115737

Jeg ser virkelig fram til svaret på deres spørsmål:
"Kan det norske selskapet bli monopolist globalt på diagnostikk og behandling av blærekreft?"

Programmet for podcasten:
Podkast 100 - live fra Kulturhuset torsdag 7. november.
Program er nå klart:
15:00 - 15:15: Mingling med god mat og drikke
15:15 - 15:45: Daniel Schneider, CEO Photocure:
> "Kan det norske selskapet bli monopolist globalt på diagnostikk og behandling av blærekreft?"
15:45 - 16:15: Torbjørn Furuseth, CFO Targovax:
“Er kombinasjonen av onkolytisk virus og sjekkpunkthemmer det som skal til for å få fart på effekten av immunterapi?”
16:15 - 16:45: Kari Grønås, lungekreftpasient og tidligere del av toppledelsen i Algeta, og Kjetil Taskén, leder for Institutt for Kreftforskning ved Oslo universitetssykehus:
“Kreftbehandling i dag og i framtiden - hva kan vi forvente oss?”
16:45 - 18:00 - Mer mat & mingling og godt drikke
Håper du kommer!

https://twitter.com/Lazarus_3D/status/1191490790805180435?s=20

https://photocure.com/news/photocure-cysview-reimbursement-further-improved-from-january-2020/

https://news.cision.com/photocure/r/photocure--cysview--reimbursement-further-improved-from-january-2020,c2954588

https://photocure.com/news/radforsk-podcast-100/

En ny strålende artikkel om BLC fra Marcus Daly Memorial Hospital.

Deler ikke linken da denne ikke virker for oss her til lands, her derfor fått tak i den direkte fra utgiver, Ravalli Republic | Montana and Bitterroot Valley News

A new urologist at Marcus Daly Memorial Hospital has been rapidly uncovering types of cancer in the Bitterroot Valley.

Kellan Clark, Doctor of Osteopathic Medicine, started in August and said the need for full-time urology services in the valley is obvious.

“We’re currently booking office appointments out to December and we’re booking surgeries well into November,” Dr. Clark said. “We save appointments for acute needs and need to save more. The ER here is quite busy with urology issues.”

From a urology standpoint, the aging population and general problems of urinary retention has been a significant part of Dr. Clark’s practice. He’s also seen a significant amount of kidney stones.

He said that in regards to cancer, in two months he has diagnosed more prostate cancer and bladder cancer than he expected.

He said the new technology is extremely valuable and with the bladder cancer. The Blue Light Cystoscopy with Cysview has proven to be effective in the cases he has used it on.

“With this technology we were finding small tumors that I otherwise wouldn’t have been able to see,” Dr. Clark said. “That has been really helpful.

“Cysview is basically a substance that you insert into the bladder with a catheter one hour before surgeryand it attaches to cancer cells within the bladder,” Dr. Clark said. “Then when you flip on the blue light with a special scope, the cancer within the bladder turns up as a bright pink, with the rest of the bladder being a blue or purplish color.”

He said, the benefit of that technology is that he can see small tumors just starting to form that he couldn’t see with the normal white light.

“Bladder cancer is a disease that is recurrent. Fifty to 60% of patients will have recurrence of what we call ‘Ta’ (a stage of a tumor) or superficial bladder cancer,” Dr. Clark said. “So, when you can find these future recurrences as they are developing then you potentially offer the patient a longer interval between treatments, a longer interval between recurrences.”

The typical course of bladder cancer is a patient would come in with complaints of symptoms of irritation or blood in their urine.

“We would perform a Cystoscopy here in the office where we would look at the bladder with a scope,” Dr. Clark said. “Then we might see a tumor. When we see a tumor the patient goes to the operating room and I go in with special equipment that resects the tumor from inside the bladder. Then you get that specimen to the lab to see if it is low grade or high grade tumor and how invasive it is.”

The results from that resection determine the next course of treatment.

“It is usually when I resect the tumor that I use the Blue Light Cystoscopy to evaluate for any other lesions that I might not be able to see otherwise,” Dr. Clark said.

In the future he may do the blue light Cystoscopy in the office just for screening purposes.

Dr. Clark recommends having symptoms checked. Blood in the urine (that you can see or detected in a “microscopic” urine test), urinary frequency, urinary urgency or a sudden change in urinary habits and irritating voiding symptoms.

“If you see blood in the urine, call me,” Dr. Clark said.

Having Blue Light Cystoscopy available locally is a major asset for the community. Marcus Daly Memorial Hospital has been the only place with it available in the northwest until recently.

“I used it pretty heavily in my training on the East Coast and I was quite surprised that there was no one in Montana, Idaho, Washington or Oregon that was doing it, until Portland recently started using it,” Dr. Clark said.

He said that often hospitals take their time before embracing new technology.

“But here I just said, ‘I think it is good for patient care, I’ve used it in the past and I’d like to bring it here’ and they said ‘sure,’” he said.

There is the potential that patients may start coming here from out-of-state for Blue Light Cystoscopy.

“It’s a tremendous service, and new technology, for a troublesome disease such as bladder cancer,” Dr. Clark said.

The rescreening timetable is different for all patients, dependent on how fast the tumor is growing and other variables.

“They have to typically come back for screening Cystoscopies after their bladder cancer has been treated, at least every six months for a few years, then annually,” Dr. Clark said. “Bladder cancer is a burdensome disease on the patient even once it has been treated. You still have surveillance and the best way is with Cystoscopies.”

Dr. Clark said Blue Light Cystoscopies have proven to be “very helpful” in cases here in the Bitterroot Valley.

“They would have probably shown up three months later, but you can see the benefit of finding those lesions early – it is fewer trips to the operating room for the patient,” he said. “Outside of skin cancer, prostate cancer is the most common cancer among men. Accordingly, I’ve diagnosed a lot more prostate cancer than bladder cancer since I’ve been here.”

Screening for prostate cancer is based off of Prostate-specific antigen (PSA) testing and rectal exams.

“The current American Urology Association (AUA) guidelines say that any man at risk for prostate cancer should have a PSA every year or every other year from age 55 to 70, and those men should also have a rectal exam, annually, for prostate cancer screening,” Dr. Clark said. “Further PSA monitoring or screening after the age 70 is then based on patient preference and their discussion with their physician.”

Similar to the need for mammograms, Dr. Clark said he sees the need for continual PSA testing.

“There are significant limitations with PSA tests but you look at not just one single number but at the trend,” Dr. Clark said. “If the PSA remains elevated over multiple occasions then the next step is a prostate biopsy to rule out prostate cancer.”

Dr. Clark said he conducts his prostate biopsies “transperineal,” with two small poke holes below the scrotum.

“The infection risk is almost completely zero and I feel it feels like it provides better biopsy samples,” he said. “I feel very strongly about that.”